Supplementary Table 1 Independent Predictors of 2-Year Mortality

Slides:

Advertisements

Similar presentations

Inappropriate clopidogrel adherence explains stent related adverse outcomes Leonardo Tamariz, MD, MPH University of Miami.

Advertisements

Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.

Table S1. Logistic regression analysis for the variables associated with the degree of change in cTnT between 2 time points (n=89) UnivariateMultivariate.

Date of download: 7/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: Long-Term Outcomes of Older Diabetic Patients After.

Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Reduced-Function CYP2C19 Genotype and Risk of Adverse.

Supplementary Appendix Thrombotic Risk Scores % of Patients Risk Categories Low Risk (n=3491) Intermediate Risk (n=2806)

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Prediction of 1-Year Mortality in Patients With Acute.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Nonfasting Glucose, Ischemic Heart Disease, and.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Dual Antiplatelet Therapy.

Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE

Harvard Clinical Research Institute, Boston, US

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Ungroup once.

Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals

Figure 1 Ischaemic endpoints

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

12 Month Outcomes in Patients with Diabetes Mellitus Implanted with a Resolute Zotarolimus-eluting Stent: Initial Results from the RESOLUTE Global Clinical.

Copyright © 2013 American Medical Association. All rights reserved.

Meta-analysis of minimally invasive coronary artery bypass versus drug-eluting stents for isolated left anterior descending coronary artery disease Ralf.

“Per Protocol” Definitions of Stent Thrombosis

Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology Prediction of 14-year cardiovascular outcomes by dobutamine.

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck

Stent Thrombosis Rates in Contemporary Clinical Practice: Insight from a Large Australian Multi-centre Registry BP Yan*, TJ Kiernan, SJ Duffy, DJ Clark,

College of Nursing ● University of Kentucky ● Lexington, KY

POISE-2 PeriOperative ISchemic Evaluation-2 Trial

Copyright © 2009 American Medical Association. All rights reserved.

Influence of Body Mass Index on Long-Term Survival After Cardiac Catheterization Barak Zafrir, MD, Ronen Jaffe, MD, Ronen Rubinshtein, MD, Basheer Karkabi,

On behalf of J. Belardi, M. Leon, L. Mauri,

on behalf of the RE-DUAL PCI Steering Committee and Investigators

First time a CETP inhibitor shows reduction of serious CV events

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Hazard ratio (HR) for mortality for a 1-kg/m2 increase in body mass index (BMI) across the range of baseline BMI among patients with acute ischemic stroke.

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Chirag Bavishi, MD, MPH,

Cardiovascular outcomes

Table. Clinical Efficacy and Safety

Meta-analysis of minimally invasive coronary artery bypass versus drug-eluting stents for isolated left anterior descending coronary artery disease Ralf.

The results of the SHARP trial

American College of Cardiology Presented by Dr. Stephan Windecker

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Management of antiplatelet therapy in patients with coronary stents undergoing noncardiac surgery: association with adverse events A. Rodriguez, N. Guilera,

Impact of clopidogrel loading dose on the safety and effectiveness of bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction:

J. Trevor Posenau, MD, Daniel M. Wojdyla, MS, Linda K

Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction P.-G. Chassot, A. Delabays, D.R. Spahn

Impact of Platelet Reactivity Following Clopidogrel Administration

Significance of Periprocedural Myocardial Infarctions in Percutaneous Coronary Interventions A New Look at an Old Topic Abhiram Prasad, MD, FRCP, FESC,

Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.

Interaction of Physical Activity and Body Mass Index on Mortality in Coronary Heart Disease: Data from the Nord-Trøndelag Health Study Trine Moholdt,

Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD Rachael L. Morton, PhD, Iryna Schlackow, DPhil, Natalie Staplin, PhD, Alastair.

Tornado diagram of one-way deterministic sensitivity analysis.

John A. Bittl et al. JACC 2016;68:

Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different.

Overall (n=301) Acute/Subacute (n=149) Late (n=152) p Presentation

Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care Marc Cohen, MD Mayo Clinic Proceedings

Impact of Diabetes Mellitus on Long-term Outcomes in the

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Shannon M. Dunlay, MD, MS, Quinn R. Pack, MD, Randal J

Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death.

Atlantic Cardiovascular Patient Outcomes Research Team

Giuseppe Gargiulo et al. JACC 2018;71:

The results of the SHARP trial

Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.

Associations between type of MI and incident HF

MRRs and EMRRs for women with ACS

Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes Steven M. Brunelli, Ravi Thadhani,

Pamela E. Scott et al. JACC 2018;71:

Risk of venous thromboembolism by ABO blood type, factor V Leiden R506Q and prothrombin G20210A mutations among individuals in the Copenhagen General.

Multivariable-adjusted HRs and 95% CIs for outcomes for waist circumference. Multivariable-adjusted HRs and 95% CIs for outcomes for waist circumference.

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Adjusted. ORs for outcomes by maintenance P2Y12 treatment

Presentation transcript:

Supplementary Table 1 Independent Predictors of 2-Year Mortality Parameter Hazard Ratio (95% CI) p-value CTE (Overall) 3.3 (2.2-4.9) <0.001 PP CTE 1.5 (0.6-3.8) 0.36 Non-PP MI 3.7 (2.2-6.2) Non-PP ST 3.7 (1.6-8.7) 0.002 AB (Overall) 3.5 (2.3-5.4) PP AB 2.5 (0.99-6.3) 0.052 Non-PP BARC type 2 2.6 (1.4-4.8) Non-PP BARC type 3 5.2 (3.0-9.1) Age (per 1 year increase) 1.03 (1.02-1.05) Prior MI 1.53 (1.1 – 2.1) 0.01 Female sex 0.70 (0.51-0.98) 0.04 Europe (vs. US) 0.64 (0.41-0.99) BMS (vs. DES) 1.8 (1.3-2.6) 0.001 Current smoking 2.1 (1.4-3.1) DM (non-Insulin requiring) 1.6 (1.1-2.2) DM (Insulin requiring) 1.9 (1.3-2.8) CrCl < 45 ml/min/1.73m2 2.7 (1.9-4.1) Hemoglobin (per 1 mg/dl increase) 0.83 (0.76-0.90) BMI ≥ 35 (versus BMI < 25) 1.7 (1.0-2.7) Hazard ratios generated from fully fitted models with CTE and AB entered as hierarchical time-varying covariates. CTE – coronary thrombotic event; AB – actionable bleeding; DM – diabetes mellitus; ACS – acute coronary syndrome; BMS – bare metal stent; DES – drug eluting stent; CrCl– creatinine clearance; PP- periprocedural; BMI – body mass index; MI – myocardial infarction

Supplementary Table 2 Mortality Hazard Ratios (95% CI) After Excluding Patients with Both Coronary Thrombotic Events and Actionable Bleeding HR (95% CI) Deaths, n CTE (Overall) 3.8 (2.3 – 6.4) 21 PP CTE 1.2 (0.4-3.9) 4 Non-PP MI 5.8 (3.0-11.3) 10 Non-PP ST 8.7 (3.4 – 22.3) 7 AB (Overall) 3.4 (2.1-5.4) 36 PP AB 1.6 (0.5-5.1) 3 Non-PP BARC type 2 2.1 (0.9 – 4.6) 11 Non-PP BARC type 3 7.3 (4.1-13.0) 22 CTE – coronary thrombotic event; AB – actionable bleeding; HR-hazard ratio; CI- confidence interval; PP – periprocedural; BARC – Bleeding Academic Research Consortium

Supplementary Table 3 Mortality Hazard Ratios (95% CI) Using Cardiac Death as Dependent Outcome HR (95% CI) Deaths, n CTE (Overall) 4.5 (2.9 – 7.2) 34 PP CTE 2.5 (0.9-6.4) 7 Non-PP MI 5.4 (2.9-10.0) 19 Non-PP ST 4.7 (1.8 – 12.3) 8 AB (Overall) 2.8 (1.7-4.8) 32 PP AB 2.8 (1.1-7.9) 4 Non-PP BARC type 2 1.8 (0.7 – 4.3) 6 Non-PP BARC type 3 3.7 (1.8-7.4) 22 CTE – coronary thrombotic event; AB – actionable bleeding; HR-hazard ratio; CI- confidence interval; PP – periprocedural; BARC – Bleeding Academic Research Consortium

Proportion of Deaths In Discrete Time Intervals After CTE or AB Supplementary Figure 1